Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gaps and paths forward in cancer pharmacology and translational research.

Frontiers in pharmacology·2026

Same author

Circulatory Disturbances in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: Mechanisms, Management, and Outcomes.

Journal of clinical medicine·2025

Same author

Left Atrial Appendage Occlusion: British Cardiovascular Intervention Society and British Heart Rhythm Society Position Statement.

Arrhythmia & electrophysiology review·2024

Same author

Left Atrial Appendage Occlusion: British Cardiovascular Intervention Society and British Heart Rhythm Society Position Statement.

Interventional cardiology (London, England)·2024

Same author

Knowledge Attainment and Engagement Among Medical Students: A Comparison of Three Forms of Online Learning.

Advances in medical education and practice·2023

Same author

Development of a Novel Tool To Demystify Drug Distribution at Tissue-Blood Barriers.

Chembiochem : a European journal of chemical biology·2023

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

In Vitro Model of Coronary Angiogenesis

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

Elevated angiogenin levels in chronic heart failure.

Jeetesh V Patel¹, Michael Sosin, Ashan Gunarathne

¹Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.

Annals of Medicine

|January 23, 2009

Summary

Circulating angiogenin levels are elevated in chronic heart failure (CHF) patients and correlate with disease severity. This protein may serve as a biomarker for heart failure progression.

Related Experiment Videos

Last Updated: Jun 26, 2026

In Vitro Model of Coronary Angiogenesis

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

Area of Science:

Cardiovascular Medicine
Biomarkers
Angiogenesis

Background:

Abnormal angiogenesis is implicated in chronic heart failure (CHF).
Circulating angiogenin, a key inducer of neovascularization, was investigated in CHF.
The study hypothesized higher angiogenin in CHF patients, linked to disease severity markers.

Purpose of the Study:

To determine if serum angiogenin levels are elevated in patients with chronic heart failure (CHF) compared to controls.
To investigate the association between circulating angiogenin levels and indicators of CHF severity, including brain natriuretic peptide (BNP), left ventricular ejection fraction (EF), and New York Heart Association (NYHA) class.

Main Methods:

A cross-sectional study design was employed.
Serum angiogenin and BNP levels were measured in 109 CHF patients and 112 controls.
Levels were correlated with echocardiographic parameters and clinical classifications.

Main Results:

Angiogenin levels were significantly higher in CHF patients versus controls (P < 0.001).
Univariate analysis showed positive associations with age, glucose, insulin, and BNP, and negative correlations with diastolic blood pressure and EF.
Multivariate analysis revealed angiogenin levels were associated with worsening NYHA class (P < 0.001) and showed moderate discriminatory power for CHF presence (AUC 0.72).

Conclusions:

Circulating angiogenin is associated with increased chronic heart failure severity, particularly NYHA class III.
Further research is needed to establish angiogenin's diagnostic and prognostic utility in CHF.